Neoplasms

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Thursday, June 27, 2019
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Lung cancer, Cancer, Neoplasms, Clinical medicine, Durvalumab, Small-cell carcinoma, AstraZeneca, Non-small-cell lung carcinoma, SCLC, PD-1 and PD-L1 inhibitors, Cancer immunotherapy, CASPIAN, small cell lung cancer, IMFINZI® (durvalumab), tremelimumab, AstraZeneca Support Programs, AstraZeneca in Lung Cancer, AstraZeneca’s Approach to Immuno-Oncology (IO), AstraZeneca in Oncology, AstraZeneca

AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.

Key Points: 
  • AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.
  • This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options.
  • IMFINZI is also being investigated following concurrent chemoradiation therapy in limited-stage SCLC in the PHASE III ADRIATIC trial.
  • IMFINZI is approved for unresectable, Stage III non-small cell lung cancer in more than 45 countries, including the US, EU and Japan, based on the Phase III PACIFIC trial.

The Osteosarcoma Institute Launches the Osteosarcoma Information Hotline

Retrieved on: 
Monday, June 24, 2019
Health, Cancer, Neoplasms, Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Oncology nursing

"Learning that you or a loved one has osteosarcoma can be devastating and overwhelming," said Lee J. Helman, MD, Director of the Osteosarcoma Institute.

Key Points: 
  • "Learning that you or a loved one has osteosarcoma can be devastating and overwhelming," said Lee J. Helman, MD, Director of the Osteosarcoma Institute.
  • "The Osteosarcoma Information Hotline was created to give patients and their families access to the reliable information and guidance they need to make informed decisions and become effective self-advocates."
  • Callers to the Osteosarcoma Information Hotline will speak with an experienced oncology nurse navigator, who will gather information and questions for review by a sarcoma expert physician.
  • The Osteosarcoma Information Hotline is provided free of charge as a service of the Osteosarcoma Institute and builds off the knowledge and experience developed by the HonorHealth Research Institute through their Virtual Online Nurse Navigation Program in other cancer types.

Sinai Researchers Find Link Between Exposure to World Trade Center Dust and Prostate Cancer

Retrieved on: 
Thursday, June 20, 2019
RTT, Cancer, Anatomy, Histopathology, Prostate cancer, Neoplasms, Prostate, Health effects arising from the September 11 attacks, Prostate-specific antigen

NEW YORK, June 20, 2019 /PRNewswire-PRWeb/ --World Trade Center (WTC) responders with prostate cancer showed signs that exposure to dust from the World Trade Center site had activated chronic inflammation in their prostates, which may have contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.

Key Points: 
  • NEW YORK, June 20, 2019 /PRNewswire-PRWeb/ --World Trade Center (WTC) responders with prostate cancer showed signs that exposure to dust from the World Trade Center site had activated chronic inflammation in their prostates, which may have contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.
  • This is the first study of people who were exposed to the WTC dust and who subsequently developed prostate cancer.
  • Our findings represent the first link between exposure to World Trade Center dust and prostate cancer."
  • Studies of the rat tissue and prostate cancer tissue samples taken from responders indicated to the Mount Sinai researchers that chronic inflammation started occurring in the prostate after exposure to the World Trade Center dust, and that inflammation may have contributed to prostate cancer.

Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference

Retrieved on: 
Thursday, June 20, 2019
Biotechnology, Health, Clinical trials, Oncology, Neoplasms, Cancer, Clinical medicine, Gastrointestinal cancer, Hereditary cancers, RTT, Familial adenomatous polyposis, Oncology, Cancer prevention, Colorectal cancer, Polyp, Polyposis registries

Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the Digestive Disease Week annual conference in San Diego.

Key Points: 
  • Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the Digestive Disease Week annual conference in San Diego.
  • FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients.
  • As such, we at the Hereditary Colon Cancer Foundation have been watching Cancer Prevention Pharmaceuticals' (CPP) recent CPP FAP-310 clinical trial closely and are encouraged by the positive results of this trial.
  • Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases.

Global Basal Cell Carcinoma Market Spotlight 2019: Key Marketed and Pipeline Drugs, Epidemiology, Clinical Trials, Patents, Licensing and Acquisition Deals, Revenue Forecasts

Retrieved on: 
Wednesday, June 19, 2019
Branches of biology, Carcinoma, Histopathology, Biology, Basal-cell carcinoma, RTT, Neoplasms, Hedgehog signaling pathway, PTCH2, Hedgehog pathway inhibitors

This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Points: 
  • This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
    The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, and hedgehog signaling pathway.
  • The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
  • There have been five licensing and asset acquisition activities involving basal cell carcinoma drugs during 2014-19.
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.

Global Gastrointestinal Stromal Tumor (GIST) Markets, 2013-2018 & 2018-2026

Retrieved on: 
Wednesday, June 19, 2019
Chemical compounds, Gastrointestinal cancer, Gastrointestinal stromal tumor, Gist, Neoplasms, Brachyury, Stromal tumor, Branches of biology, Pyridines, Pyrimidines

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the gastrointestinal stromal tumor (GIST) market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and drug-specific revenue forecasts
    The report estimates that in 2017, there were 97,900 incident cases of gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to 107,200 incident cases by 2026.
  • The overall likelihood of approval of a Phase I solid tumor asset is 5.7%, and the average probability a drug advances from Phase III is 39.4%.
  • Novartis also leads industry sponsors with by far the highest number of overall clinical trials for GIST.

New York Mesothelioma Victims Center Now Urges an Electrician or Plumber with Mesothelioma Anywhere in New York to Call Them for Direct Access to Attorney Erik Karst of Karst von Oiste-Get Better Compensation

Retrieved on: 
Wednesday, June 19, 2019
Asbestos, Cancer, Health, Neoplasms, Mesothelioma, RTT

The Internet can be a confusing place to find a mesothelioma law firm-even for people in New York.

Key Points: 
  • The Internet can be a confusing place to find a mesothelioma law firm-even for people in New York.
  • https://www.karstvonoiste.com/
    The New York Mesothelioma Victims Center specializes in assisting specific types of people with mesothelioma in New York including electricians, plumbers, skilled trades workers and Navy Veterans.
  • These groups account for over half the people who will be diagnosed with mesothelioma in New York State each year.
  • However, based on the calls the Mesothelioma Victims Center receives a diagnosed victim of mesothelioma could live in any state including New York.

Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

Retrieved on: 
Wednesday, June 19, 2019
RTT, Histopathology, Prostate cancer, Neoplasms, Cancer, Clinical medicine, Active surveillance of prostate cancer, Cancer vaccine

"We believe that data from a single Phase 3 trial, if successful, will be sufficient to support market approval in Europe."

Key Points: 
  • "We believe that data from a single Phase 3 trial, if successful, will be sufficient to support market approval in Europe."
  • The Phase 3 study design, agreed upon by the EMA, will enroll patients with a confirmed diagnosis of intermediate risk disease.
  • Prostate cancer is the second most common form of cancer in men in the United States with an estimated 175,000 new cases in 2019.
  • Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases.

Global Basal Cell Carcinoma Market Spotlight Report 2019 Featuring Sun Pharmaceutical, Novartis, Roche, & Valeant Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019
Health, Oncology, Pharmaceutical, Branches of biology, Carcinoma, Histopathology, Basal-cell carcinoma, RTT, Biology, Neoplasms, Hedgehog signaling pathway, PTCH2, Hedgehog pathway inhibitors

The "Market Spotlight: Basal Cell Carcinoma" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Basal Cell Carcinoma" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
    The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, and hedgehog signaling pathway.
  • The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.

Small-Cell Lung Cancer (SCLC) Market Spotlight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 18, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Cancer, Clinical medicine, Neoplasms, Carcinoma, Cytopathology, Small-cell carcinoma, Nivolumab, Bristol-Myers Squibb, SCLC, Lung cancer, Topotecan, Combined small-cell lung carcinoma

The "Market Spotlight: Small-Cell Lung Cancer (SCLC)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Small-Cell Lung Cancer (SCLC)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, licensing and acquisition deals, and drug-specific revenue forecasts
    The report estimates that in 2017, there were 310,300 incident cases of small cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 339,500 incident cases by 2026.
  • Celgene's Amrubicin, Novartis's Hycamtin (topotecan), Aeterna's Lobaplatin, and Bristol-Myers Squibb's Opdivo (nivolumab) are the only marketed drugs for SCLC.
  • The majority of industry-sponsored drugs in active clinical development for SCLC are in Phase II, with only one drug in the NDA/BLA phase.